Related Experiment Video

Updated: May 24, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

489

Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies

Sidhi Laksono1, Grace T Hosea2, Zahra Nurusshofa3

  • 1Siloam Diagram Heart Hospital, Cinere, Indonesia; Faculty of Medicine, Universitas Muhammadiyah Prof Dr Hamka, Tangerang, Indonesia.

The Brown Journal of Hospital Medicine
|March 6, 2025
PubMed

Insights

Diabetic cardiomyopathy, a heart condition in diabetes patients, involves ventricular dysfunction. Sodium-glucose cotransporter-2 inhibitors are preferred treatments, with emerging therapies needing more research.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus and heart failure share a complex bidirectional relationship.
  • Diabetic cardiomyopathy is ventricular dysfunction in diabetes patients, independent of atherosclerosis and hypertension.
  • Pathophysiological mechanisms include lipotoxicity, oxidative stress, and mitochondrial dysfunction.

Purpose of the Study:

  • To review the pathophysiology of diabetic cardiomyopathy.
  • To examine cardiac structural changes associated with diabetes.
  • To discuss novel glucose-lowering therapies and targeted treatments for diabetic cardiomyopathy.

Main Methods:

  • Literature review of existing studies on diabetic cardiomyopathy.
  • Analysis of research on the mechanisms and cardiac effects of diabetes.
  • Evaluation of current and emerging therapeutic strategies.

Main Results:

  • Diabetes induces cardiac structural changes contributing to heart failure.
  • Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are now a preferred glucose-lowering therapy for diabetic patients with heart failure.
  • Emerging targeted therapies demonstrate potential benefits requiring further investigation.

Conclusions:

  • Understanding the pathophysiology of diabetic cardiomyopathy is crucial for effective management.
  • SGLT-2 inhibitors represent a significant advancement in treating diabetic cardiomyopathy.
  • Further research into novel and targeted therapies is warranted to improve patient outcomes.

Keywords:
Diabetes mellitusSGLT-2diabetic cardiomyopathyheart failuretargeted therapy

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

111
Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

10.1K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
222
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
360
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
488
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
839
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K